T. Rowe Price Associates’s Immunovant IMVT Stock Holding History
Bought
Maintained
Sold
Other funds holding IMVT
T. Rowe Price Associates's IMVT Position: Q3 2026 in Review
T. Rowe Price Associates reduced its Immunovant (IMVT) stake by 1.3% in Q3 2026, selling an estimated $927K and leaving 1,805,676 shares worth $61M. The position accounts for 0.01% of the portfolio, ranked #796.
T. Rowe Price Associates first reported a position in IMVT in Q3 2020 and has held it in 21 quarters since. The position peaked at $70.5M in Q2 2026. 232 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.
- T. Rowe Price Associates held 1,805,676 shares of Immunovant worth $61M as of Q3 2026.
- T. Rowe Price Associates sold 23,534 Immunovant shares in Q3 2026, an estimated $927K.
- Immunovant made up 0.01% of T. Rowe Price Associates's portfolio in Q3 2026, its #796 holding.
- T. Rowe Price Associates first reported a position in Immunovant in Q3 2020 and has held it in 21 quarters since.
- T. Rowe Price Associates's Immunovant position peaked at $70.5M in Q2 2026.
- 232 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.
Based on T. Rowe Price Associates's 13F filing for Q3 2026, filed 16 Nov 2026.